Welcome to our dedicated page for Cardiff Oncology news (Ticker: CRDF), a resource for investors and traders seeking the latest updates and insights on Cardiff Oncology stock.
Cardiff Oncology, Inc. develops clinical-stage cancer therapies centered on PLK1 inhibition and its lead oral inhibitor onvansertib. Company news commonly covers onvansertib in RAS-mutated metastatic colorectal cancer, including the CRDF-004 Phase 2 program evaluating combinations with standard-of-care regimens such as FOLFIRI/bevacizumab and FOLFOX/bevacizumab.
Updates also include preclinical and investigator-initiated work in other oncology settings, including metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, triple-negative breast cancer, HER2-low breast cancer models and chronic myelomonocytic leukemia. Corporate releases also address oncology conference presentations, key opinion leader events, executive appointments, investor conferences and Nasdaq inducement equity grants.
Cardiff Oncology (Nasdaq: CRDF) reported promising Phase 1b/2 results for its lead KRAS-mutated metastatic colorectal cancer program, showcasing an objective response rate (ORR) of 34% compared to historical controls of 5-13%. Additionally, Phase 2 data from its metastatic castration-resistant prostate cancer trial indicated that 75% of patients on the highest dose achieved disease control. The company holds approximately $129.4 million in cash as of March 31, 2022, with increased operating expenses attributed to development efforts for onvansertib. These results position Cardiff for future growth and advancement in oncology.
Cardiff Oncology (Nasdaq: CRDF) announced the departure of its Chief Medical Officer, Katherine L. Ruffner, M.D., effective April 22, 2022. Dr. Ruffner will assist during the transition, while Sandra L. Silberman, M.D., Ph.D., will serve as the interim senior medical advisor overseeing clinical trials. The company's clinical development efforts for its primary drug candidate, onvansertib, remain on track. CEO Mark Erlander expressed gratitude for Dr. Ruffner's contributions and optimism for the year ahead.
Cardiff Oncology announced updated clinical data from its Phase 2 trial evaluating onvansertib combined with abiraterone and prednisone for metastatic castration-resistant prostate cancer (mCRPC). The trial shows increased disease control rates with higher dose densities of onvansertib—from 29% to 45% for PSA stabilization and 53% to 75% for radiographic stable disease. Median progression-free survival increased from 4.1 months to 13.2 months in patients receiving onvansertib. Genomic analysis suggests sensitivity to the combination treatment correlates with mutations in MTOR and PTEN.
Cardiff Oncology (Nasdaq: CRDF) announced promising results from preclinical studies at the AACR Annual Meeting, showcasing that the combination of onvansertib and the PARP inhibitor olaparib significantly improves survival in PARPi-resistant ovarian cancer models. The studies demonstrated that this combination therapy was well tolerated and effective against various PDX models, including both BRCA1-mutant and wild-type variants. These findings support further investigation into this treatment approach for overcoming resistance to PARP inhibitors in clinical settings.
Cardiff Oncology, a clinical-stage biotechnology company, announced that CEO Mark Erlander will present at the 2022 Virtual Growth Conference from March 28-30, 2022. The fireside chat is scheduled for March 28 at 2:30 PM ET. The conference will be hosted by Maxim Group LLC and streamed live on M-Vest. Additionally, Dr. Erlander will provide a pre-recorded overview of the company's clinical and corporate strategy. Cardiff Oncology focuses on developing therapies targeting cancers using its lead asset, onvansertib, a PLK1 inhibitor. For more information, visit their website.
Cardiff Oncology (Nasdaq: CRDF) announced the acceptance of two abstracts for poster presentations at the AACR Annual Meeting from April 8-13, 2022 in New Orleans. The presentations focus on their lead asset, onvansertib, a promising PLK1 inhibitor. The first abstract discusses biomarkers for mCRPC patients receiving onvansertib with abiraterone, while the second highlights combination therapy's potential against PARP inhibitor resistance. These findings aim to advance treatment options for cancer patients.
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology firm, will join Cowen's 42nd Annual Healthcare Conference for a panel discussion and investor meetings from March 7-9, 2022. The panel, focusing on Gastrointestinal/Genitourinary Oncology, is scheduled for March 8, 2022, at 10:30 AM ET. Cardiff is advancing its lead drug, onvansertib, a third-generation PLK1 inhibitor, aimed at treating various cancers including KRAS-mutated colorectal cancer. A replay of the panel will be accessible on Cardiff's website for 30 days post-conference.
Cardiff Oncology (Nasdaq: CRDF) reported significant progress in its KRAS-mutated metastatic colorectal cancer (mCRC) program, with patient numbers increasing from 14 to 48. Initial data showed a robust objective response rate of 35% and a median progression-free survival (mPFS) of 9.4 months. A $15 million equity investment from Pfizer at a premium of 19% per share further supports the company's growth. Total operating expenses for Q4 2021 increased to $9.6 million, largely due to ongoing clinical programs. The company ended 2021 with approximately $141 million in cash.
On January 31, 2022, Cardiff Oncology (Nasdaq: CRDF) announced the granting of stock options to a new employee, totaling 55,008 shares. The options, priced at $3.38 per share, reflect the stock's closing price on the grant date. These inducements are in compliance with Nasdaq Listing Rule 5635(c)(4) and will vest over four years, contingent on the employee's continued employment. Cardiff Oncology focuses on innovative cancer treatments, including its investigational drug, onvansertib, targeting KRAS-mutated cancers and other high-need indications.
Cardiff Oncology, a clinical-stage oncology company targeting unmet medical needs in cancer treatment, announced its participation in the B. Riley Securities 2022 Oncology Conference, scheduled for January 27-28, 2022. The company will present on January 28, 2022, at 2:00 PM ET. Their lead investigational drug, onvansertib, is a first-in-class Polo-like Kinase 1 (PLK1) inhibitor, currently evaluated in three clinical programs focused on KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer. A replay of the presentation will be available post-conference.